Test Price
2,800 AED✅ Home Collection Available
IGHM Gene Agammaglobulinemia Type 1, Autosomal Recessive Genetic Test in UAE | 2800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
This next-generation sequencing (NGS) test provides 99.9% diagnostic sensitivity for autosomal recessive agammaglobulinemia type 1, certified under ISO 9001:2015 processing standards. The test is conducted at DNA Labs UAE, a DHA-licensed facility (License No. 1143) in Dubai Healthcare City.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM).
- Clinical Guidance: Post-Test Telephonic Guidance by DHA-licensed Clinical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
- Regulatory Compliance: Federal Decree-Law No. 45 of 2021 (PDPL), Federal Law No. 2 of 2019 (Health ICT), and Federal Decree-Law No. 4 of 2016 (Medical Liability).
Test Overview & Methodology
This targeted next-generation sequencing (NGS) test screens the entire coding region of the IGHM gene for pathogenic variants responsible for autosomal recessive agammaglobulinemia type 1 – a severe primary immunodeficiency characterized by absent B cells and profound hypogammaglobulinemia. Confirmatory genetic diagnosis enables immediate initiation of immunoglobulin replacement therapy, prophylactic antibiotics, and family-wide carrier screening. The test achieves 30x coverage depth with 99.9% analytical sensitivity and specificity.
Our Test – IGHM NGS
- Targeted NGS (30x coverage) of entire IGHM coding region
- 99.9% analytical sensitivity & specificity
- TAT: 3–4 weeks
- 2,800 AED (all-inclusive)
- Peripheral whole blood (EDTA) – single tube
- Includes genetic counselling & clinical report
Closest Alternative – WES/IgG Panel
- Whole Exome Sequencing (average depth <20x)
- Lower diagnostic yield for agammaglobulinemia
- TAT: 6–8 weeks
- Cost: 5,000–7,500 AED
- Incidental findings burden
- May lack dedicated phenotype-driven interpretation
Physician Insight & Safety Protocols
“This targeted IGHM gene analysis is a cornerstone for confirming autosomal recessive agammaglobulinemia, enabling precise clinical decisions and family planning. While our NGS detects virtually all pathogenic single-nucleotide variants and small indels, I always counsel that results must be correlated with serum immunoglobulins, flow cytometry, and clinical phenotype. Never alter treatment regimens—especially immunoglobulin replacement—without direct physician supervision.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Medication Safety
Do not discontinue any prescribed medication (especially immunoglobulin replacement or prophylactic antibiotics) without consulting your doctor.
- IVIG Window: If receiving intravenous immunoglobulin, wait at least 3 weeks post-infusion for accurate baseline blood sampling.
- Home Collection: Available daily 8 AM – 11 PM; ensure no active febrile illness at time of draw.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Do not schedule home collection if you currently have an active severe infection or febrile illness; postpone until recovery.
- Red Flags for ER: If you or the child experiences respiratory distress, cyanosis, or septic shock, seek emergency care immediately—do not wait for genetic test results.
- Minors: Informed consent from legal guardian mandatory per Federal Decree-Law No. 4 of 2016 (Medical Liability); genetic counselling must be provided prior to testing.
Patient FAQ & Clinical Guidance
1. What exactly does the IGHM gene test detect, and why is it ordered?
This NGS detects pathogenic mutations in the IGHM gene that cause autosomal recessive agammaglobulinemia type 1, a complete B-cell deficiency. Clinicians order it when an infant or child presents with recurrent severe bacterial infections, extremely low immunoglobulins, and absent B cells on flow cytometry, or when there is a family history of the disease. The targeted approach avoids the complexity and cost of whole-exome sequencing while providing near‑100% sensitivity for the responsible gene.
2. How should I prepare for the blood draw, and what safety measures are in place?
No fasting or special diet is required; simply provide your clinical history and any previous immunoglobulin level reports to the phlebotomist. Our DHA‑licensed mobile team uses cold‑chain EDTA tubes and ISO 9001:2015‑certified transport to guarantee sample integrity. Collection is available daily from 8 AM to 11 PM, and patients with active infections must postpone the draw until recovered to avoid misleading results.
3. How are my genetic data protected under UAE law, and what happens after the result?
All genetic information is safeguarded under Federal Decree-Law No. 45 of 2021 (UAE Personal Data Protection Law) and Federal Law No. 2 of 2019 (ICT in Health Fields). Data is processed solely within our certified facility in Dubai. You will receive a detailed clinical report interpreted by a DHA‑licensed clinical geneticist, followed by a telephonic consultation to discuss the findings. Positive results trigger a recommended family counselling session to construct a pedigree and offer cascade testing for at‑risk relatives.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic and clinical data are encrypted, stored within the UAE, and accessed only by authorized personnel. Patient consent is obtained in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability. Our facility is DHA-licensed (License No. 1143) and operates under ISO 9001:2015 certified quality management systems.
Clinical & Logistical Metadata
| Test Name | IGHM Gene Agammaglobulinemia Type 1, Autosomal Recessive Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks (21–28 days) |
| Sample Type / Matrix | Peripheral whole blood (EDTA) |
| Methodology Used | Next-generation sequencing (NGS) – targeted gene analysis |
| ICD-10-CM Code | D80.0 |
| LOINC Code | 33288-0 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians